Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financing

Set Alert for Financing

Grey Wolf Raises $49m To Bring ‘Tumor Unmasking’ Candidate To Clinic

The UK biotech will use the funds to advance the development of its first-in-class ERAP1 inhibitor, which could circumvent the limitations of poor tumor visibility and T cell exhaustion.

Financing Cancer

The Hunt For Big Fish: How KDDF Is Helping Create Korean Deals

Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.

South Korea Deals

Finch To Wind Down, Seek Value For Pipeline Assets And IP

Following two workforce cuts in 2022, Finch said it will cut its staff by 95%, halting a Phase III study of lead recurrent C. diff candidate CP101 and seeking to maximize shareholder value.

Restructuring Business Strategies

Finance Watch: Fundraising Shows Preference For Later-Stage Companies

Recent financings, including the $150m launch of Pathalys and a planned $100m IPO for Mineralys, illustrate the reality of biopharma funding in 2023 – that having near-term clinical trial milestones are key to fundraising this year. Companies with dwindling cash are conserving the funds they have left.

Financing Business Strategies

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: the best of J.P. Morgan; Novartis on its US-first commercial plan; Chugai CEO talks to Scrip on the Roche alliance and more; Scrip Asks what this year holds for pricing and reimbursement; and the global outlook for biopharma funding.

Business Strategies Commercial

Financing Available For Some, But Not All Biopharma Companies In 2023

Investors, advisors and CEOs at the J.P. Morgan Healthcare Conference and Biotech Showcase were somewhat optimistic about fundraising this year, but noted certain companies may have to call it quits.

Financing Deals

Latest Big Rounds Herald A China Biotech Funding Spring?

Around the turn of the year, four Chinese biotechs including Kelun Biotech and BioRay ramped up funding with deals worth more than $100m, at a time when overall investment sentiment in the sector remains gloomy.

China Financing

Big Antibody Deals Offer Hope Amid Challenging Times For China Biotech

Recent antibody mega-deals are providing a rare bright spot for the embattled China biotech sector, amid sharply rising COVID-19 deaths in the country that indicate rebound and recovery could take longer than previously expected.

China Coronavirus COVID-19

Biopharma Funding Contracted Last Year – And 2023 Will See The Squeeze Continue

Now the pandemic-era biotech boom is over, biopharma companies and investors are both adjusting their financing strategies to survive and even thrive in the new environment.

Commercial Companies

Scrip Asks…What Does 2023 Hold For Biopharma? Part 3: Global Headwinds

Headwinds of political instability, violent conflict, inflation and recession accompany us into 2023. Scrip surveyed industry leaders on the impacts for biopharma.

Scrip Asks Business Strategies

Finance Watch: Sun Shines On Biotech Stocks As J.P. Morgan Ends

Public Company Edition: Also, Johnson & Johnson’s consumer health spin-out Kenvue filed paperwork to get the ball rolling on an initial public offering. In addition, Geron raised $198m and Madrigal accessed more than $300m after positive trial readouts, but layoffs were revealed by Editas, Elevation, Nabriva and others.

Financing Restructuring

J.P. Morgan Was Back, But Not With A Roar

Biopharma executives and investors descended on San Francisco again, but the numbers seemed fewer, the weather was volatile and the outlook for the sector remained uncertain.  

Strategy Deals
See All
UsernamePublicRestriction

Register